诺和诺德Novo Nordisk (NVO) 2016年年度报告「NYSE」.pdf

1、novo nordiskANNUAL REPORT2016DEFINING TIMES FOR THE US BUSINESSRISK MANAGEMENT Protecting long-term value creationA NEW ERA OF DIABETES TREATMENT?All references can be found on p 113.The Management review,as defined by the Danish Financial Statements Act,is found on pp 156 and 97.This Annual Report

2、is Novo Nordisks full statutory Annual Report pursuant to Section 149 of the Danish Financial Statements Act.A printed extract of this statutory Annual Report is available in English upon request.Further,a shortened printed version,consisting of the Management review and excerpts from the consolidat

3、ed statements,is available in Danish upon request.In the event of any discrepancies,the full statutory Annual Report shall prevail.The patients portrayed in this Annual Report have participated of their own accord and solely to express their personal opinions on topics referred to in the articles in

4、 which they appear.Use of their pictures as illustrations is in no way intended to associate them with the promotion of any Novo Nordisk products.Any and all views and opinions expressed by patients in this report are solely their own.They have been invited to be included,and were in no way coerced.

5、The views and opinions they express are entirely their own,and do not necessarily reflect the views and opinions of Novo Nordisk.CONTENTS01 Letter from the Chairman02 Letter from the former CEO 03 Letter from the new CEO04 Novo Nordisk at a glance06 2016 performance and 2017 outlook14 Performance hi

6、ghlights16 Our strategy18 Doing business the Novo Nordisk Way20 Pipeline overview22 Changing Diabetes24 A new era of diabetes treatment?26 Changing diabetes One city at a time28 Living with the stigma of obesity 30 Changing haemophilia32 Defining times for the US business36 The only constant in Inte